This site is intended for healthcare professionals
News

Positive results from GENESIS Phase III trial of motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma .BioLineRx Ltd

Read time: 2 mins
Last updated:28th Jun 2021
Published:9th May 2021
BioLineRx Ltd. announced positive top-line results from the Company's GENESIS Phase III trial evaluating its lead clinical candidate, motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.
Condition: Stem Cell Transplantation
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest